Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
Pluri Inc. (Nasdaq: PLUR, TASE: PLUR) is a leading biotechnology company that transforms cells into solutions to promote global wellbeing and sustainability. The company’s core business revolves around developing cell-based products for medical, agricultural, and industrial applications using its proprietary three-dimensional (3D) cell expansion technology. This innovative platform can grow cells in mass quantities with batch-to-batch consistency, making it suitable for applications ranging from regenerative medicine to food technology and beyond.
Pluri's flagship technology leverages placental expanded (PLX) cells that are derived from placental tissue. These cells release biomolecules such as cytokines, chemokines, and growth factors which aid in the healing of damaged tissues by stimulating the body’s natural regenerative mechanisms. The company operates a state-of-the-art manufacturing facility approved by the FDA, EMA, and PMDA, ensuring high standards and regulatory compliance.
In recent developments, Pluri has made significant strides in the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product. The company secured a patent from the Israel Patent Office, further establishing its leadership in 3D cell expansion technology. Pluri’s cell-based coffee production method can significantly reduce water usage and farmland requirements, addressing the environmental challenges faced by traditional coffee farming.
Pluri is also advancing in the field of immune cell therapies. The company unveiled a novel method for expanding immune cells and obtained a U.S. patent for this technology, which mimics the natural environment of lymph nodes. This method ensures the integrity and functionality of immune cells, opening new possibilities for treatments of immune disorders and neurodegenerative diseases.
The company actively collaborates with various strategic partners to enhance its technological capabilities and explore new market opportunities. For instance, Pluri partnered with Wilk Technologies to develop cultured human and animal milk products for the elderly, aiming to address the growing demand for medical foods tailored to the nutritional needs of older adults.
Financially, Pluri is well-positioned with robust intellectual property, boasting over 140 active and granted patents. The company continues to expand its market presence, driven by a strong commitment to innovation and sustainability.
To stay updated on Pluri Inc.'s latest news and developments, visit the company’s official website at www.pluri-biotech.com or follow them on LinkedIn and X.
Ever After Foods (EAF) and Bühler announced a strategic collaboration to develop commercial-scale cultivated meat production systems. The partnership aims to bring to market a production system that enables commercial production at ten-fold lower scale than existing technologies.
The collaboration leverages EAF's proprietary edible packed-bed (EPB™) technology platform, which can reduce production costs by over 90% while achieving superior production efficiency. The system enables natural production of both muscle and fat tissues for beef, chicken, duck, and fish cells, ensuring exceptional replication of conventional meat.
EAF's technology offers enhanced nutritional value and superior flavor, working with select cultivated meat companies and industry leaders to accelerate global deployment. The partnership with Bühler aims to develop tailored solutions for sustainable scaling of cultivated meat production, moving beyond pharma-based technologies toward food-specific production methods.
Pluri Inc. (PLUR) has secured an additional $3.5 million investment from Merchant Adventure Fund, L.P., a major existing shareholder, bringing total recent financings to $10 million. The investment follows a recent $6.5 million private placement with global investor Alejandro Weinstein.
The new investment involves issuing 759,219 common shares at $4.61 per share and warrants to purchase 45,553 shares at $5.568 per share. The closing is expected around February 20, 2025. The recent $6.5 million investment from Weinstein includes an agreement to acquire Kokomodo and potentially enter the cacao market.
The funds will support Pluri's growth strategy as a global leader in cell-based technology, enabling expansion across pharma, foodtech, and agtech industries. The company views this additional investment as a strong vote of confidence in its vision, technology, and execution strategy.
Pluri Inc. (PLUR) has secured a $6.5 million strategic investment from global investor Alejandro Weinstein at $4.61 per share, representing a premium to market. The investment includes common shares, warrants, and pre-funded warrants. Concurrently, Pluri is acquiring a 71% stake in Kokomodo , an AgTech company specializing in cultivated cacao production, for $4.5 million in Pluri common shares.
The transactions aim to strengthen Pluri's position in sustainable food technologies. As part of the deal, Weinstein will join Pluri's Board of Directors. The investment closing is expected around January 31, 2025, while the Kokomodo acquisition is anticipated to complete in Q2 2025. Both transactions require shareholder approval and other regulatory clearances.
The global cacao market, valued at $13.5 billion in 2023, is projected to reach $23.5 billion by 2030 with an 8.2% CAGR.
Pluri Inc. (PLUR) congratulates Mesoblast on receiving FDA approval for the first MSC-based therapy treating steroid-refractory acute graft-versus-host disease (SR-aGVHD). This milestone validates the therapeutic potential of Mesenchymal Stromal Cell (MSC) therapies in regenerative medicine. Pluri's CEO Yaky Yanay emphasized how this approval marks a significant advancement in cellular medicine and demonstrates the potential of regenerative therapies to transform healthcare by addressing root causes rather than just symptoms.
Pluri continues developing its proprietary 3D cell-expansion technology for MSC therapies, including PLacental eXpanded cells for treating conditions like Acute Radiation Syndrome and Knee Osteoarthritis.
Pluri Inc. (Nasdaq: PLUR) has been shortlisted for the CDMO of the Year Award by the Advanced Therapies Awards 2025 for its PluriCDMO™ business division. Launched in January 2024, PluriCDMO™ offers contract development and manufacturing services to life science companies, providing access to their 47,000 square foot GMP facilities and patented bioreactor system for 3D cell expansion.
The nomination comes less than a year after the division's launch, highlighting Pluri's rapid progress in supporting transformative therapies. The company's technology enables mass-scale production through a fully controlled, automated, and validated process, serving a growing number of innovative clients in the cell therapy industry.
Pluri Inc. (Nasdaq: PLUR) is evaluating its readiness for mass production of PLX-R18, a potential treatment for hematopoietic complications of acute radiation syndrome (H-ARS). The assessment comes amid heightened global nuclear threats, particularly in Ukraine. PLX-R18 has shown promise in improving survival and accelerating recovery from H-ARS in preclinical studies, with support from U.S. defense agencies. The treatment has received FDA's Orphan Drug Designation and IND approval for H-ARS treatment. The company's manufacturing facility is equipped for large-scale cellular therapy production and could be mobilized for mass production if needed.
Pluri Inc. (NASDAQ: PLUR), a biotechnology company specializing in cell-based solutions, has announced its participation in the upcoming Q4 Virtual Investor Summit Microcap Event on November 21st. The company will deliver a presentation from 9:00 AM to 9:30 AM ET and will be available for one-on-one meetings throughout the day.
The event showcases 40 micro-cap companies with catalysts and strong market performance. It features live Q&A sessions and is complimentary for qualified investors. The presentation will be accessible via webcast.
BrainStorm Cell Therapeutics has signed a Memorandum of Understanding (MOU) with Pluri to manufacture NurOwn® for the planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This agreement will enable BrainStorm to transfer its manufacturing technology and start production at Pluri's GMP-compliant facility in Israel upon finalizing a definitive agreement. The collaboration aims to meet the supply requirements for the Phase 3b trial and explore future commercial distribution options, pending NurOwn's approval. The trial will enroll up to 200 participants and is designed in two parts: a 24-week double-blind period followed by a 24-week open-label period. The primary endpoint is the change in ALSFRS-R score from baseline to week 24. BrainStorm will provide further updates in Q4 2024.
Pluri Inc. (PLUR) announces a collaboration with Bar-Ilan University's BIRAD, funded by the Israel Innovation Authority, to advance cancer immunotherapy using Placental Mucosal Associated Invariant T (MAIT) cells for solid tumors. The partnership combines Pluri's proprietary MAIT cell expansion platform with Prof. Cyrille Cohen's Siglec-based Chimeric Switch Receptors technology to enhance CAR-MAIT's efficacy and tumor specificity. The project aims to develop innovative allogeneic cell therapies targeting solid tumors, addressing a significant unmet medical need. Pluri's MAIT cells, derived from human placentas, offer unique advantages including potency, multiple tumor-targeting mechanisms, and reduced risk of Graft versus Host Disease.
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) has signed a tech transfer and manufacturing agreement with Kadimastem (TASE: KDST) through its PluriCDMO™ division. PluriCDMO™ will manufacture two cell therapy product candidates for Kadimastem: AstroRx® for ALS treatment and IsletRx for diabetes treatment. This collaboration leverages Pluri's 47,000 square foot GMP cell production facility and expertise in developing and manufacturing cell-based products. The agreement supports Kadimastem's preparation for clinical trials and expansion into the U.S. market, particularly for an upcoming FDA Phase 2a study of AstroRx®. This partnership highlights PluriCDMO™'s versatility and commitment to advancing innovative life-saving therapies.
FAQ
What is the current stock price of Pluri (PLUR)?
What is the market cap of Pluri (PLUR)?
What is Pluri Inc. known for?
What are PLX cells?
What recent achievements has Pluri Inc. made?
How does Pluri’s cell-based coffee benefit the environment?
What partnerships has Pluri Inc. entered into recently?
What is Pluri's approach to immune cell therapies?
What markets does Pluri Inc. operate in?
How many patents does Pluri Inc. hold?
Where can I find more information about Pluri Inc.?
What is PLX-R18?
